The core activity of MiHKAL GmbH is the research and development of new medicines, particularly antidepressants, through the synthesis and development of small molecules and psychoactive compounds.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Research and development of novel drug candidates for depressive disorders and PTSD, including a preclinical pipeline with MKL001 and MKL002 as well as proof-of-concept studies.
CRO Services
CRO Services for preclinical research, mechanism-of-action validation and study support in the field of small molecules and prodrugs.
Knowledge
No knowledge articles yet
Once MiHKAL GmbH has claimed this profile, we'll publish editorial articles and case studies here together.